Saroja Devi Geetha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Saroja Devi Geetha has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Karen Chau
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, New York, USA
5 shared publicationsAnam Khan
Department of Pathology and Laboratory Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, United States
3 shared publicationsArvind Rishi
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
3 shared publicationsAtif Khan
Department of Pathology and Laboratory Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, United States
3 shared publicationsDeepika Savant
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
3 shared publicationsKasturi Das
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, New York, USA
3 shared publications
Latest Publications
- 22 September 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
Uterine Tumor Resembling Ovarian Sex Cord Tumor With GREB1::NCOA2 Fusion and Neuroendocrine Marker Expression: A Case Report and Literature Review
The uterine tumor resembling ovarian sex cord tumor (UTROSCT) is a rare mesenchymal tumor of the uterus. Morphological patterns can show sheets, cords, and trabeculae that are similar to those seen in ovarian sex cord-stromal tumors. Immunohistochemically, they exhibit a polyphenotypic variable pattern, including epithelial, myoid, and sex cord lineage as well as hormone receptors. We report a female patient with a UTROSCT harboring a GREB1::NCOA2 fusion that demonstrated a diffuse, strong positivity with chromogranin, synaptophysin, and CD56. INSM1 was performed to rule out true neuroendocrine differentiation. While neuroendocrine marker expression is rare in UTROSCT, this report adds to the limited literature describing this unusual immunoprofile, particularly in the context of GREB1 rearrangements. This study remains important to highlight the inclusion of this type of immunohistochemical staining in the spectrum of features UTROSCT can represent. Recent systematic review evidence suggests that GREB1 -rearranged UTROSCTs may represent a biologically and clinically distinct subset from ESR1 -rearranged tumors, with differences in clinicopathological features and molecular characteristics.
- 22 September 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
Uterine Tumor Resembling Ovarian Sex Cord Tumor With GREB1::NCOA2 Fusion and Neuroendocrine Marker Expression: A Case Report and Literature Review
The uterine tumor resembling ovarian sex cord tumor (UTROSCT) is a rare mesenchymal tumor of the uterus. Morphological patterns can show sheets, cords, and trabeculae that are similar to those seen in ovarian sex cord-stromal tumors. Immunohistochemically, they exhibit a polyphenotypic variable pattern, including epithelial, myoid, and sex cord lineage as well as hormone receptors. We report a female patient with a UTROSCT harboring a GREB1::NCOA2 fusion that demonstrated a diffuse, strong positivity with chromogranin, synaptophysin, and CD56. INSM1 was performed to rule out true neuroendocrine differentiation. While neuroendocrine marker expression is rare in UTROSCT, this report adds to the limited literature describing this unusual immunoprofile, particularly in the context of GREB1 rearrangements. This study remains important to highlight the inclusion of this type of immunohistochemical staining in the spectrum of features UTROSCT can represent. Recent systematic review evidence suggests that GREB1 -rearranged UTROSCTs may represent a biologically and clinically distinct subset from ESR1 -rearranged tumors, with differences in clinicopathological features and molecular characteristics.
- Open Access
- 4 June 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (7) , 1800-1805
Cytologic and Surgical Correlation of TERT -Mutated Indeterminate Thyroid Nodules: A Case Series
Introduction: Telomerase reverse transcriptase ( TERT ) promoter mutations is a relatively novel mutation that has been linked with thyroid cancers. This study examines the frequency, cytology and histo-morphologic features, and clinical outcomes of TERT -mutated indeterminate thyroid nodules. Methods: A retrospective review of Bethesda III and IV thyroid cytology specimen sent for ThyroSeq ® testing (2019-2022) was performed, selecting those with TERT mutations. Demographics, cytologic features, surgical diagnoses, and follow-up data were analyzed. Results: Among 567 specimens tested, 12 (2%) harbored TERT mutations; 4 had TERT alone, and 8 had additional mutations. Average age of patients was 69 years (92% > 50 years). Eight had surgical follow-up: 50% were malignant, 25% were benign and 25% were of uncertain malignant potential. Additionally, 62% were oncocytic nodules. Clinical follow-up showed all evaluated patients were alive without recurrences or metastases at last contact. Conclusion: In our cohort, TERT promoter mutations were rare in indeterminate thyroid nodules (2%) and frequently accompanied by additional molecular changes. It is more frequently detected in older patients. Unlike prior reports describing TERT mutations exclusively in malignant thyroid tumors, our findings encompassed a broader histological spectrum, including benign, uncertain malignant potential and malignant lesions.
- 4 June 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (7) , 1800-1805
Open AccessCytologic and Surgical Correlation of TERT -Mutated Indeterminate Thyroid Nodules: A Case Series
Introduction: Telomerase reverse transcriptase ( TERT ) promoter mutations is a relatively novel mutation that has been linked with thyroid cancers. This study examines the frequency, cytology and histo-morphologic features, and clinical outcomes of TERT -mutated indeterminate thyroid nodules. Methods: A retrospective review of Bethesda III and IV thyroid cytology specimen sent for ThyroSeq ® testing (2019-2022) was performed, selecting those with TERT mutations. Demographics, cytologic features, surgical diagnoses, and follow-up data were analyzed. Results: Among 567 specimens tested, 12 (2%) harbored TERT mutations; 4 had TERT alone, and 8 had additional mutations. Average age of patients was 69 years (92% > 50 years). Eight had surgical follow-up: 50% were malignant, 25% were benign and 25% were of uncertain malignant potential. Additionally, 62% were oncocytic nodules. Clinical follow-up showed all evaluated patients were alive without recurrences or metastases at last contact. Conclusion: In our cohort, TERT promoter mutations were rare in indeterminate thyroid nodules (2%) and frequently accompanied by additional molecular changes. It is more frequently detected in older patients. Unlike prior reports describing TERT mutations exclusively in malignant thyroid tumors, our findings encompassed a broader histological spectrum, including benign, uncertain malignant potential and malignant lesions.
- Open Access
- 24 April 2026
- Published by Wiley in Diagnostic Cytopathology
- Vol. 54 (7) , 519-527
Quantitative Analysis of Cytologic Features: Application to Mucoepidermoid Carcinoma
Introduction: Cytologic diagnosis relies on recognition of morphologic features, yet the diagnostic value of individual cytologic features or their combinations is rarely quantified. In this study, we apply a quantitative cytologic feature analysis (QCFA) approach that treats each cytologic feature as a diagnostic test with measurable performance characteristics. Using mucoepidermoid carcinoma (MEC) as a model, we systematically assess and quantify the diagnostic utility of individual and combined cytomorphologic features. Methods: In this retrospective study (2002–2021), 95 salivary gland fine needle aspirates in which MEC was considered in the differential diagnosis were reviewed. Two cytopathologists scored 16 predefined features, including extracellular mucin and three types of vacuolated cells: mucocytes (columnar or cuboidal glandular cells with single mucin‐filled vacuoles and eccentric nuclei), epimucocytes (similar to mucocytes but with a dense squamoid cytoplasmic rim), and non‐mucinous empty vacuolated cells (containing sharply circumscribed empty vacuoles). Cytologic findings were correlated with follow‐up histology, and contingency table analysis was used to calculate sensitivity, specificity, and likelihood ratios. Results: Of 95 cases, 49 (51.6%) were confirmed as MEC on histology. Epimucocytes were the most sensitive feature (0.90), while intermediate cells were the most specific (0.94). Extracellular mucin, mucocytes, and epidermoid cells were also predictive of MEC, whereas non‐mucinous empty vacuolated cells were negatively associated with MEC (LR − = 2.3). The combination of any mucinous feature (epimucocytes, mucocytes, or extracellular mucin) with either intermediate or squamous cells yielded optimal diagnostic performance (specificity 91%, LR + 8.9). Conclusions: QCFA provides objective, quantitative support for established cytologic diagnostic criteria. Using MEC as a model, we introduce a standardized definition for epimucocytes and provide the first quantitative assessment of their diagnostic value. This study demonstrates the feasibility and value of applying rigorous quantitative metrics to individual and combined cytologic features, offering a systematic approach to evaluating morphologic criteria.
- 24 April 2026
- Published by Wiley in Diagnostic Cytopathology
- Vol. 54 (7) , 519-527
Open AccessQuantitative Analysis of Cytologic Features: Application to Mucoepidermoid Carcinoma
Introduction: Cytologic diagnosis relies on recognition of morphologic features, yet the diagnostic value of individual cytologic features or their combinations is rarely quantified. In this study, we apply a quantitative cytologic feature analysis (QCFA) approach that treats each cytologic feature as a diagnostic test with measurable performance characteristics. Using mucoepidermoid carcinoma (MEC) as a model, we systematically assess and quantify the diagnostic utility of individual and combined cytomorphologic features. Methods: In this retrospective study (2002–2021), 95 salivary gland fine needle aspirates in which MEC was considered in the differential diagnosis were reviewed. Two cytopathologists scored 16 predefined features, including extracellular mucin and three types of vacuolated cells: mucocytes (columnar or cuboidal glandular cells with single mucin‐filled vacuoles and eccentric nuclei), epimucocytes (similar to mucocytes but with a dense squamoid cytoplasmic rim), and non‐mucinous empty vacuolated cells (containing sharply circumscribed empty vacuoles). Cytologic findings were correlated with follow‐up histology, and contingency table analysis was used to calculate sensitivity, specificity, and likelihood ratios. Results: Of 95 cases, 49 (51.6%) were confirmed as MEC on histology. Epimucocytes were the most sensitive feature (0.90), while intermediate cells were the most specific (0.94). Extracellular mucin, mucocytes, and epidermoid cells were also predictive of MEC, whereas non‐mucinous empty vacuolated cells were negatively associated with MEC (LR − = 2.3). The combination of any mucinous feature (epimucocytes, mucocytes, or extracellular mucin) with either intermediate or squamous cells yielded optimal diagnostic performance (specificity 91%, LR + 8.9). Conclusions: QCFA provides objective, quantitative support for established cytologic diagnostic criteria. Using MEC as a model, we introduce a standardized definition for epimucocytes and provide the first quantitative assessment of their diagnostic value. This study demonstrates the feasibility and value of applying rigorous quantitative metrics to individual and combined cytologic features, offering a systematic approach to evaluating morphologic criteria.
- 1 April 2026
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 83, 152641
Can large language models like ChatGPT and Gemini interpret cervical cytology accurately?
- 1 April 2026
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 83, 152641
Can large language models like ChatGPT and Gemini interpret cervical cytology accurately?
- 11 March 2026
- Published by Wiley in Diagnostic Cytopathology
- Vol. 54 (6) , 436-443
Classifying Liver Cytology Using the WHO Reporting System: Institutional Experience and Malignancy Risk Assessment
Aim: The World Health Organization's (WHO) Reporting System for Liver Cytopathology aims to standardize communication with clinicians globally to improve patient management. Our study reclassifies liver cytology reports based on the WHO classification and assesses the risk of malignancy (ROM) in each category. Methods: Liver cytology reports from 2019 to 2023 were retrieved to obtain demographic details, clinical data, cytology, and surgical follow‐up (SFU). Cytology diagnoses were reclassified using the WHO classification. ROM was analyzed based on SFU. Results: Our study had 976 cases, age ranged from 1–96 years, with an average age of 67 years. Male: female ratio was 1:1. Majority of lesions (400/525, 76%) were less than 5 cm. Location of the lesion was available in 595 cases, with right lobe being the most common (64%; n = 383), followed by left lobe (36%, n = 212). 883 cases (90%) underwent rapid onsite evaluation. Reclassification using the WHO classification system into 5 categories included non‐diagnostic ( n = 79), benign ( n = 117), atypical ( n = 25), suspicious for malignancy ( n = 6) and malignant ( n = 749). Thirty‐one cases (3%) had cytology follow up, 71(7.3%) had SFU. The ROM in the SFU cohort was 17% (1/6; 95% CI: 10%–76%) in non‐diagnostic, 23% (3/13, 95% CI: 15.4%–30.6%) in benign and 100% in atypical (3/3, 95% CI: 88%–100%), suspicious for malignancy (2/2, 95% CI: 50%–100%) and malignant(47/47, 95% CI: 99.5%–100%) categories. Repeat FNA yielded malignant upgrade rates of 80% (4 out of 5) in non‐diagnostic and 75% (3 out of 4) in atypical categories. Conclusion: We present the values of ROM in the various categories of the WHO Reporting System for Liver Cytopathology using a large cohort of cases. Repeat sampling is recommended in non‐diagnostic and atypical categories based on an increase in malignant upgrades in these categories.
- 11 March 2026
- Published by Wiley in Diagnostic Cytopathology
- Vol. 54 (6) , 436-443
Classifying Liver Cytology Using the WHO Reporting System: Institutional Experience and Malignancy Risk Assessment
Aim: The World Health Organization's (WHO) Reporting System for Liver Cytopathology aims to standardize communication with clinicians globally to improve patient management. Our study reclassifies liver cytology reports based on the WHO classification and assesses the risk of malignancy (ROM) in each category. Methods: Liver cytology reports from 2019 to 2023 were retrieved to obtain demographic details, clinical data, cytology, and surgical follow‐up (SFU). Cytology diagnoses were reclassified using the WHO classification. ROM was analyzed based on SFU. Results: Our study had 976 cases, age ranged from 1–96 years, with an average age of 67 years. Male: female ratio was 1:1. Majority of lesions (400/525, 76%) were less than 5 cm. Location of the lesion was available in 595 cases, with right lobe being the most common (64%; n = 383), followed by left lobe (36%, n = 212). 883 cases (90%) underwent rapid onsite evaluation. Reclassification using the WHO classification system into 5 categories included non‐diagnostic ( n = 79), benign ( n = 117), atypical ( n = 25), suspicious for malignancy ( n = 6) and malignant ( n = 749). Thirty‐one cases (3%) had cytology follow up, 71(7.3%) had SFU. The ROM in the SFU cohort was 17% (1/6; 95% CI: 10%–76%) in non‐diagnostic, 23% (3/13, 95% CI: 15.4%–30.6%) in benign and 100% in atypical (3/3, 95% CI: 88%–100%), suspicious for malignancy (2/2, 95% CI: 50%–100%) and malignant(47/47, 95% CI: 99.5%–100%) categories. Repeat FNA yielded malignant upgrade rates of 80% (4 out of 5) in non‐diagnostic and 75% (3 out of 4) in atypical categories. Conclusion: We present the values of ROM in the various categories of the WHO Reporting System for Liver Cytopathology using a large cohort of cases. Repeat sampling is recommended in non‐diagnostic and atypical categories based on an increase in malignant upgrades in these categories.
- 26 December 2025
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (4) , 997-1006
Clinicopathologic Features of Six Patients With Metastatic Carcinoma to the Uterine Cervix
Metastasis to the female genital tract is a rare event and presents a significant diagnostic challenge. Among the organs of the female genital tract, the uterine cervix is an exceptionally uncommon site for metastasis, likely due to its limited vascular perfusion and abundant fibrous tissue. The most common clinical presentation is abnormal vaginal bleeding, seen in 62% to 75% of patients. Accurate identification of cervical tumors, whether primary or metastatic, is necessary for proper treatment and prognostic assessment. In this case series, we present the clinicopathologic features of six patients with metastatic cancer to the uterine cervix encountered over a 5-year period.
- 26 December 2025
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (4) , 997-1006
Clinicopathologic Features of Six Patients With Metastatic Carcinoma to the Uterine Cervix
Metastasis to the female genital tract is a rare event and presents a significant diagnostic challenge. Among the organs of the female genital tract, the uterine cervix is an exceptionally uncommon site for metastasis, likely due to its limited vascular perfusion and abundant fibrous tissue. The most common clinical presentation is abnormal vaginal bleeding, seen in 62% to 75% of patients. Accurate identification of cervical tumors, whether primary or metastatic, is necessary for proper treatment and prognostic assessment. In this case series, we present the clinicopathologic features of six patients with metastatic cancer to the uterine cervix encountered over a 5-year period.
- Open Access
Diagnostic Utility of TRPS1 Immunohistochemistry in Primary and Metastatic Breast Carcinoma with Special Emphasis on Spindle Cell Neoplasms of the Breast
Introduction: Breast cancer, a major contributor to cancer-related deaths in females, presents significant challenges in classification and diagnosis, particularly triple negative breast cancers (TNBC). This study explores the utility of Trichorhinophalangeal syndrome type 1 (TRPS1) as a novel biomarker, comparing its efficacy with GATA3 in TNBC with a specific focus on spindle cell neoplasms. Methods: Our pathology database was searched to identify breast carcinoma cases between January 2021 and July 2021. All cases of poorly differentiated breast carcinoma (primary and metastatic) and primary spindle cell neoplasms of breast confirmed on core biopsies, in women greater than 18 years were selected. Immunohistochemical staining for ER, PR, HER2, GATA3 and TRPS1 were interpreted by two pathologists. TRPS1 and GATA3 expression levels among different groups were analyzed. Results: Our study cohort comprised of 60 cases (24 primary breast carcinomas, 22 metastatic breast carcinomas and 14 spindle cell lesions of the breast). Our study revealed TRPS1’s superior sensitivity in TNBC, with 84% positivity compared to 53% for GATA3. TRPS1 showed promise in diagnosing spindle cell neoplasms, identifying 6/14 (43%) of cases, while GATA3 yielded no positive results. The six spindle cell cases that were TRPS1 positive were one synovial sarcoma, two malignant phyllodes, one fibromatosis, one myofibroblastoma and one angiosarcoma. Conclusion: TRPS1 holds substantial promise as a sensitive and novel diagnostic marker for TNBC in comparison to GATA3. The differential diagnostic utility of TRPS1 warrants careful consideration due to its positivity in other spindle cell neoplasms of the breast, which may present as differential diagnoses for metaplastic carcinoma. Highlights: TRPS1 demonstrated superior sensitivity (84%) compared to GATA3 (53%) in identifying triple-negative breast carcinomas (TNBC), supporting its role as a promising diagnostic marker. TRPS1, unlike GATA3, showed positivity in 43% of spindle cell breast neoplasms, including malignant phyllodes, fibromatosis, myofibroblastoma, angiosarcoma, and synovial sarcoma, highlighting its broader expression spectrum. Pathologists should exercise caution in interpreting TRPS1 positivity within spindle cell lesions, as its expression may mimic metaplastic carcinoma, underscoring the need for careful correlation with morphology and other markers.
Open AccessDiagnostic Utility of TRPS1 Immunohistochemistry in Primary and Metastatic Breast Carcinoma with Special Emphasis on Spindle Cell Neoplasms of the Breast
Introduction: Breast cancer, a major contributor to cancer-related deaths in females, presents significant challenges in classification and diagnosis, particularly triple negative breast cancers (TNBC). This study explores the utility of Trichorhinophalangeal syndrome type 1 (TRPS1) as a novel biomarker, comparing its efficacy with GATA3 in TNBC with a specific focus on spindle cell neoplasms. Methods: Our pathology database was searched to identify breast carcinoma cases between January 2021 and July 2021. All cases of poorly differentiated breast carcinoma (primary and metastatic) and primary spindle cell neoplasms of breast confirmed on core biopsies, in women greater than 18 years were selected. Immunohistochemical staining for ER, PR, HER2, GATA3 and TRPS1 were interpreted by two pathologists. TRPS1 and GATA3 expression levels among different groups were analyzed. Results: Our study cohort comprised of 60 cases (24 primary breast carcinomas, 22 metastatic breast carcinomas and 14 spindle cell lesions of the breast). Our study revealed TRPS1’s superior sensitivity in TNBC, with 84% positivity compared to 53% for GATA3. TRPS1 showed promise in diagnosing spindle cell neoplasms, identifying 6/14 (43%) of cases, while GATA3 yielded no positive results. The six spindle cell cases that were TRPS1 positive were one synovial sarcoma, two malignant phyllodes, one fibromatosis, one myofibroblastoma and one angiosarcoma. Conclusion: TRPS1 holds substantial promise as a sensitive and novel diagnostic marker for TNBC in comparison to GATA3. The differential diagnostic utility of TRPS1 warrants careful consideration due to its positivity in other spindle cell neoplasms of the breast, which may present as differential diagnoses for metaplastic carcinoma. Highlights: TRPS1 demonstrated superior sensitivity (84%) compared to GATA3 (53%) in identifying triple-negative breast carcinomas (TNBC), supporting its role as a promising diagnostic marker. TRPS1, unlike GATA3, showed positivity in 43% of spindle cell breast neoplasms, including malignant phyllodes, fibromatosis, myofibroblastoma, angiosarcoma, and synovial sarcoma, highlighting its broader expression spectrum. Pathologists should exercise caution in interpreting TRPS1 positivity within spindle cell lesions, as its expression may mimic metaplastic carcinoma, underscoring the need for careful correlation with morphology and other markers.
- Open Access
Evaluating Large Language Models in Interpreting Cervical Cytology
Background: Large language models (LLMs) have shown promise in medical imaging, but their utility in cytology remains underexplored. This study evaluates GPT-5 and Gemini 2.5 Pro for Pap smear interpretation. Methods: Digital cervical Pap smear images of 100 cases were obtained from the Hologic Education Site, with Hologic diagnoses considered the gold standard. Representative images were uploaded into GPT-5 and Gemini 2.5 Pro and prompted to provide a diagnosis based on the Third Edition of the Bethesda System for Reporting Cervical Cytopathology. Cases with infectious organisms were assessed using additional images. Concordance was evaluated at exact diagnosis and clinical management groupings, wherein diagnoses with similar management implications were grouped. Sensitivity and specificity for abnormal cytology were also calculated. Results: Concordance of both LLMs for exact diagnostic matches were comparable (GPT-5: 47%, Gemini: 48%) and increased to 66% for clinical management grouping. GPT-5 performed best for low-grade squamous intraepithelial lesions (75%), whereas Gemini 2.5 Pro showed the highest concordance in the high-grade squamous intraepithelial lesion (HSIL) category (82%), although this was largely attributable to its strong tendency to overcall cases as HSIL. Sensitivity for detecting abnormal cytology was 74% for GPT-5 and 84% for Gemini, with specificity of 74% and 71%, respectively. GPT-5 better identified glandular lesions, while Gemini detected organisms more accurately (71% vs. 20%). Conclusions: Current LLMs demonstrate moderate ability to identify cytologic abnormalities but are not yet reliable for independent Pap smear interpretation. Targeted fine-tuning, prompt optimization, and cytology-specific training could enhance their utility as adjunctive tools in cytology workflows.
Open AccessEvaluating Large Language Models in Interpreting Cervical Cytology
Background: Large language models (LLMs) have shown promise in medical imaging, but their utility in cytology remains underexplored. This study evaluates GPT-5 and Gemini 2.5 Pro for Pap smear interpretation. Methods: Digital cervical Pap smear images of 100 cases were obtained from the Hologic Education Site, with Hologic diagnoses considered the gold standard. Representative images were uploaded into GPT-5 and Gemini 2.5 Pro and prompted to provide a diagnosis based on the Third Edition of the Bethesda System for Reporting Cervical Cytopathology. Cases with infectious organisms were assessed using additional images. Concordance was evaluated at exact diagnosis and clinical management groupings, wherein diagnoses with similar management implications were grouped. Sensitivity and specificity for abnormal cytology were also calculated. Results: Concordance of both LLMs for exact diagnostic matches were comparable (GPT-5: 47%, Gemini: 48%) and increased to 66% for clinical management grouping. GPT-5 performed best for low-grade squamous intraepithelial lesions (75%), whereas Gemini 2.5 Pro showed the highest concordance in the high-grade squamous intraepithelial lesion (HSIL) category (82%), although this was largely attributable to its strong tendency to overcall cases as HSIL. Sensitivity for detecting abnormal cytology was 74% for GPT-5 and 84% for Gemini, with specificity of 74% and 71%, respectively. GPT-5 better identified glandular lesions, while Gemini detected organisms more accurately (71% vs. 20%). Conclusions: Current LLMs demonstrate moderate ability to identify cytologic abnormalities but are not yet reliable for independent Pap smear interpretation. Targeted fine-tuning, prompt optimization, and cytology-specific training could enhance their utility as adjunctive tools in cytology workflows.
- Open Access
- 8 June 2025
- Published by S. Karger AG in Pathobiology
- p. 1-13
Transdifferentiation of Multiple Myeloma into Histiocytic Sarcoma: Case report of a highly unusual phenomenon
Introduction Transdifferentiation of multiple myeloma (MM) into histiocytic sarcoma (HS) is exceptionally rare. We report a unique case, confirming this phenomenon through cytogenetics and molecular analyses. Case Presentation A 46-year-old woman with high-risk light chain MM developed extramedullary disease despite multiple lines of therapy. Biopsies revealed atypical histiocytic proliferation consistent with HS. Shared immunoglobulin gene rearrangements, cytogenetic alterations, and gene mutations, including a rare BRAF L485F, confirmed clonal relatedness between the two neoplasms. IGH::MAF translocation specific to MM and IGVH somatic hypermutation in HS suggests divergent evolution from a putative germinal center B-cell (GCB) precursor. Conclusions This case highlights lineage plasticity of MM to undergo HS transdifferentiation, potentially mediated through a mutated common GCB precursor antecedent to the plasma cell stage, and the subsequent development of HS and MM through acquisition of additional genetic events. Recognition of this exceptional phenomenon and understanding its underlying mechanism have implications for diagnosis, classification, and personalized treatment.
- 8 June 2025
- Published by S. Karger AG in Pathobiology
- p. 1-13
Open AccessTransdifferentiation of Multiple Myeloma into Histiocytic Sarcoma: Case report of a highly unusual phenomenon
Introduction Transdifferentiation of multiple myeloma (MM) into histiocytic sarcoma (HS) is exceptionally rare. We report a unique case, confirming this phenomenon through cytogenetics and molecular analyses. Case Presentation A 46-year-old woman with high-risk light chain MM developed extramedullary disease despite multiple lines of therapy. Biopsies revealed atypical histiocytic proliferation consistent with HS. Shared immunoglobulin gene rearrangements, cytogenetic alterations, and gene mutations, including a rare BRAF L485F, confirmed clonal relatedness between the two neoplasms. IGH::MAF translocation specific to MM and IGVH somatic hypermutation in HS suggests divergent evolution from a putative germinal center B-cell (GCB) precursor. Conclusions This case highlights lineage plasticity of MM to undergo HS transdifferentiation, potentially mediated through a mutated common GCB precursor antecedent to the plasma cell stage, and the subsequent development of HS and MM through acquisition of additional genetic events. Recognition of this exceptional phenomenon and understanding its underlying mechanism have implications for diagnosis, classification, and personalized treatment.